Last reviewed · How we verify
Coromec Registry with ECL-19
Coromec Registry with ECL-19 is a Small molecule drug developed by Aventyn, Inc.. It is currently in Phase 2 development for Phase 2 clinical trials for Coromec Registry with ECL-19 are ongoing, but no specific indications have been reported.. Also known as: Glycocheck.
Coromec Registry with ECL-19 is a small molecule that targets the molecular target.
Coromec Registry with ECL-19 is a small molecule that targets the molecular target. Used for Phase 2 clinical trials for Coromec Registry with ECL-19 are ongoing, but no specific indications have been reported..
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Coromec Registry with ECL-19 |
|---|---|
| Also known as | Glycocheck |
| Sponsor | Aventyn, Inc. |
| Target | ECL-19 |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of Coromec Registry with ECL-19 is not well understood, but it is believed to work by interacting with the molecular target, leading to a therapeutic effect.
Approved indications
- Phase 2 clinical trials for Coromec Registry with ECL-19 are ongoing, but no specific indications have been reported.
Common side effects
- Unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coromec Registry with ECL-19 CI brief — competitive landscape report
- Coromec Registry with ECL-19 updates RSS · CI watch RSS
- Aventyn, Inc. portfolio CI
Frequently asked questions about Coromec Registry with ECL-19
What is Coromec Registry with ECL-19?
How does Coromec Registry with ECL-19 work?
What is Coromec Registry with ECL-19 used for?
Who makes Coromec Registry with ECL-19?
Is Coromec Registry with ECL-19 also known as anything else?
What development phase is Coromec Registry with ECL-19 in?
What are the side effects of Coromec Registry with ECL-19?
What does Coromec Registry with ECL-19 target?
Related
- Target: All drugs targeting ECL-19
- Manufacturer: Aventyn, Inc. — full pipeline
- Indication: Drugs for Phase 2 clinical trials for Coromec Registry with ECL-19 are ongoing, but no specific indications have been reported.
- Also known as: Glycocheck
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing